As an FDA advisory panel meets Wednesday to vote on whether to recommend approval of Sanofi’s MS drug Lemtrada, patient opinion leaders have already voiced their view. A small majority told ...

Fatigue is experienced by approximately 80% of people with multiple sclerosis, significantly impacting their quality of life and functional ability. To discuss the latest advancements in fatigue ...

In a significant advance for multiple sclerosis (MS) research, a new study has uncovered a potential link between certain initial symptoms and long-term disability outcomes. The research, published in ...

There is currently no cure for Multiple Sclerosis (MS). Patients rarely do well with no therapy at all, and it is generally recommended that patients with a confident diagnosis of MS begin treatment ...

Researchers conducted a cohort study that suggests oral N-acetylglucosamine treatment can hinder neurodegeneration and inflammation associated with multiple sclerosis (MS). Oral treatment of ...

Growing skin plaques with scale Increased incidence may be related to interferon beta exposure during treatment for multiple sclerosis. Patients with multiple sclerosis (MS) have a high rate of ...

A significant portion of patients with multiple sclerosis (MS) can achieve a stable disease state when treated with modern disease-modifying therapy (DMT), especially when started early in the disease ...

“This study found that having bladder problems was significantly associated with lower well-being in [people with] MS, particularly when considering OAB. Bowel problems, self-management of bladder ...

In a longitudinal cohort study, patients with multiple sclerosis underwent cognitive evaluation and magnetic resonance imaging scans at baseline and after 3 years. Memory decline was observed in ...